DUBLIN–(BUSINESS WIRE)–The “Hepatitis C – Competitive Landscape in 2021” report has been added to ResearchAndMarkets.com’s offering.
Hepatitis C – Competitive Landscape in 2021 combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.
In hepatitis C, Nonstructural proteins 5A (NS5A) and 5B (NS5B) are major targets of drug developers. There are 138 drugs in the pipeline with 90% molecules present in early stage development. Large Pharma dominates R&D in this indication, with Gilead Sciences leading the way. More frequent use of newer direct-acting antiviral therapies (DAAs) is expected to drive the market, but Steady decline in overall patient pool and high cost of newer DAAs are expected to limit the market growth.
This reports provides a data-driven overview of the current and future competitive landscape in hepatitis C therapeutics.
Scope
Components of the report include:
- Disease epidemiology
- Marketed drugs assessment
- Pipeline drugs assessment
- Clinical trials assessment
- Commercial assessment
- Social media overview
- Digital marketing overview
Reasons to Buy
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global hepatitis C market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global Hepatitis C market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.
Key Topics Covered:
1 Preface
1.1 Table of Contents
1.2 Abbreviations
1.3 Related Reports
1.4 Upcoming Related Reports
2 Executive Summary
2.1 Key Findings
2.2 Key Events
3 Introduction
3.1 Report Scope
3.2 Disease Overview Epidemiology Overview
3.3 Epidemiology
4 Marketed Drugs Assessment
4.1 Marketed Drugs Overview
4.2 Marketed Drug Profiles
5 Pipeline Assessment
5.1 Pipeline Overview
5.2 Pipeline Breakdown by Region
5.3 Pipeline Breakdown by Molecule Type and Target
5.4 Drug Review Designations
5.5 Phase Transition Success Rates
5.6 Likelihood of Approval
6 Clinical Trial Assessment
6.1 Clinical Trials Overview by Phase
6.2 Overview by Region
6.4 Therapy Area Perspective
6.4 Leading Sponsors
6.5 Enrollment Analytics
6.6 Feasibility Analysis
7 Commercial Assessment
7.1 Upcoming Market Catalysts
8 Social Media and Digital Marketing
8.1 Key Twitter Chatter
8.2 Top Branded Websites
8.3 Trust Flow and Citation Flow
9 Appendix
For more information about this report visit https://www.researchandmarkets.com/r/auc2pi
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900